Here's the reader question in late 2023, as the first CRISPR-based medicine nears the finish line: the therapy works on the science, but how is the revenue divided between the two companies that made it? The answer is a number in the filing — equally.
CRISPR Therapeutics' Form 10-Q filed November 6, 2023 describes the joint development agreement under which it and Vertex pursue hemoglobinopathy treatments, including exa-cel. The filing states that the company and Vertex would share equally all research and development costs and worldwide revenues. That phrase — share equally — is the entire economic spine of the program as restructured.
Strip away the headlines and the 2022 annual report, filed February 21, 2023 adds the clinical definition: exa-cel is an investigational, autologous, ex vivo CRISPR gene-edited hematopoietic stem-cell therapy. Define that plainly — autologous means it uses the patient's own cells; ex vivo means the editing happens outside the body; hematopoietic stem cells are the blood-forming cells. The patient's cells are edited and returned, with the aim of a one-time fix for inherited blood disorders.
Why does the split matter as much as the science? Because a 50/50 economic structure tells you how to read every future revenue dollar: half flows to each partner, and so does half the cost. A reader who assumes the company named CRISPR captures the upside of the first CRISPR medicine would be wrong by half. The 10-Q is explicit that costs and revenues are shared equally.
Be careful about timing. As of these 2023 filings, exa-cel is described as investigational — a candidate under regulatory review, not yet a commercial product on these documents. The 50/50 terms are the rules that will govern the money if and when sales begin. The 10-K describes the candidate; the economics are forward-looking from here.
The EdgarBeast evidence index, which surfaces and normalizes SEC filings, makes it possible to line up the clinical description and the economic terms from the same company's filings. The story they tell together: a landmark gene-editing therapy whose revenues, by contract, are split down the middle.